Tam, C., Seymour, J., Shen, J., Michel, J., Yazdy, M. S., Brown, P., Rose, S., Takai, M., Thompson, M., Levin, M., Munir, T., Ghia, P., Sharman, J. (2025). CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor. Blood. https://doi.org/10.1182/blood-2025-8245